Incidence Rate of Covid-19 Infection in People with Fourth Dose of Vaccines Bivalent Mrna from October 2022 to October 2023 in A General Medicine Office in Toledo (Spain)
{"title":"Incidence Rate of Covid-19 Infection in People with Fourth Dose of Vaccines Bivalent Mrna from October 2022 to October 2023 in A General Medicine Office in Toledo (Spain)","authors":"J. Luis Turabián","doi":"10.31579/2639-4162/133","DOIUrl":null,"url":null,"abstract":"Background Incidence rate of covid-19 infection in people vaccinated with 4th dose of RNA covid-19 vaccine remain subject of debate and is not clearly known Objective Estimate the incidence rate of covid-19 in vaccinated 4th dose people in general practitioner care level. Methodology An incidence rates epidemiological analysis of covid-19 infection in people with 4th dose of bivalent mRNA vaccines based in a longitudinal study from October, 2022 to October, 2023, in a general practice setting in Toledo, Spain. Results 21 cases of covid-19 infection in vaccinated people with 4th dose were included. Incidence rate of covid-19 infection in total vaccinated people with 4th dose from October 2022 to October 2023 was 2%; it was greater in > = 65 years vs. < 65 years (3% vs. 1%), and in women vs. men (2% vs. 1%). Regarding incidence rate of covid-19 infection in vaccinated people with 4th dose in general population of the office was 1%; It was again older at > = 65 years vs. < 65 years (1% vs. 0.5%), but without differences between women and men (1% vs. 1%). Conclusion In general practice setting in Toledo, Spain, crude incidence rate of covid-19 infection in vaccinated people with 4th dose and in general population of the office was low. However, the population segments of >= 65 years and women, even with fourth vaccine dose, have a higher risk of covid-19 infection, and consequently should continue receiving booster vaccine. But these results should be interpreted with caution since the number of tests carried out in the community was low","PeriodicalId":93288,"journal":{"name":"General medicine and clinical practice","volume":"22 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General medicine and clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2639-4162/133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background Incidence rate of covid-19 infection in people vaccinated with 4th dose of RNA covid-19 vaccine remain subject of debate and is not clearly known Objective Estimate the incidence rate of covid-19 in vaccinated 4th dose people in general practitioner care level. Methodology An incidence rates epidemiological analysis of covid-19 infection in people with 4th dose of bivalent mRNA vaccines based in a longitudinal study from October, 2022 to October, 2023, in a general practice setting in Toledo, Spain. Results 21 cases of covid-19 infection in vaccinated people with 4th dose were included. Incidence rate of covid-19 infection in total vaccinated people with 4th dose from October 2022 to October 2023 was 2%; it was greater in > = 65 years vs. < 65 years (3% vs. 1%), and in women vs. men (2% vs. 1%). Regarding incidence rate of covid-19 infection in vaccinated people with 4th dose in general population of the office was 1%; It was again older at > = 65 years vs. < 65 years (1% vs. 0.5%), but without differences between women and men (1% vs. 1%). Conclusion In general practice setting in Toledo, Spain, crude incidence rate of covid-19 infection in vaccinated people with 4th dose and in general population of the office was low. However, the population segments of >= 65 years and women, even with fourth vaccine dose, have a higher risk of covid-19 infection, and consequently should continue receiving booster vaccine. But these results should be interpreted with caution since the number of tests carried out in the community was low